Mink Therapeutics Inc.

06/23/2026 | Press release | Distributed by Public on 06/23/2026 08:10

Proxy Results (Form 8-K)

Item 5.07 Submission of Matters to a Vote of Security Holders.

The Company held its Annual Meeting of Stockholders (the "Annual Meeting") on June 17, 2026. A total of 3,277,906 shares of common stock, representing 65.79% of the shares outstanding and eligible to vote and constituting a quorum, were present at the Annual Meeting or represented by valid proxies. At the Annual Meeting, the Company's stockholders voted on the following matters, which are described in detail in the Company's Definitive Proxy Statement filed with the U.S. Securities and Exchange Commission on April 23, 2026: (i) to elect Garo Armen, Barbara Ryan and John Holcomb as Class II Directors, each for a term of three years expiring at the 2029 Annual Meeting of Stockholders ("Proposal 1"), (ii) to ratify the appointment of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 ("Proposal 2").

The Company's stockholders elected each of the Class II Director nominees nominated for election in Proposal 1 at the Annual Meeting. The Company's stockholders voted for the Class II Directors as follow:

Class II Director Nominees

For

Against

Withheld

Broker Non-Votes

Garo Armen

2,363,360

0

32,898

881,648

Barbara Ryan

2,362,760

0

33,498

881,648

John Holcomb

2,381,491

0

14,767

881,648

The Company's stockholders approved Proposal 2. The votes cast at the Annual Meeting were as follows:

For

Against

Abstain

Broker Non-Votes

3,249,124

26,560

2,222

0


Mink Therapeutics Inc. published this content on June 23, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on June 23, 2026 at 14:11 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]